Biovian Oy. (3/16/23). "Press Release: Remedium Bio and Biovian Have Agreed to Collaborate on Remedium’s First-in-Class Disease Modifying AAV Gene Therapy for Osteoarthritis".

	Organisation	Biovian Oy
	Organisation 2	Remedium Bio Inc.
	Product	contract manufacturing (biologicals)
	Product 2	RMD 1101 AAV gene therapy (Remedium Bio)
	Person	Nieminen, Antti (Biovian 202303 CEO + Co-Founder)
	Person 2	Luppino, Frank (Remedium Bio 202303 CEO)

Remedium Bio, a Boston-area gene therapy company developing treatments for a range of large clinical unmet needs in rheumatology, endocrinology, and age-related diseases, and Biovian Oy, a globally operating Nordic CDMO for biopharmaceuticals, have agreed on a collaboration for AAV drug development. The agreement covers Remedium’s lead candidate, a first-in-class disease-modifying treatment for Osteoarthritis (OA) under the name RMD 1101. Biovian has agreed to include Remedium’s lead candidate in Biovian’s AAV manufacturing platform development program. Biovian’s second-generation AAV platform will be built around a selected high-productivity and state-of-the-art quality suspension-based HEK293 cell line, with full scalability to 200L and utilizing chromatography for standard purification. Biovian has invented a robust way to efficiently separate full capsids from empty capsids, applicable to large-scale manufacturing.

Antti Nieminen, CEO at Biovian: "We are pleased to start a collaboration with Remedium Bio and to include Remedium’s AAV candidate in our ongoing second-generation AAV platform development program. Remedium’s therapeutic candidate will be important in the validation of Biovian’s second generation AAV platform – bringing a new level of quality and efficiency to the viral vector manufacturing space”.

Frank Luppino, President and CEO at Remedium Bio: “Having recently generated one of the most comprehensive preclinical efficacy datasets in Osteoarthritis and presented at the 2023 Orthopedic Research Society meeting, we are extremely excited to scale production of our lead candidate RMD 1101 to support Toxicology and Clinical demand. Partnering with Biovian’s high-productivity viral vector manufacturing process will enable clinical supply and cost-effective production at eventual commercial scale for a disease that impacts hundreds of millions of people around the globe.”

About Remedium Bio

Remedium Bio, Inc., is a Boston area biotechnology company focused on the development of curative therapies for a broad range of pathologies. The company is founded on the vision of changing lives via curative breakthroughs, grounded in combining proven scientific fundamentals in novel ways, to treat well-characterized pathologies. Remedium’s current lead candidate is a disease-modifying treatment for Osteoarthritis that is based on the clinically validated mechanism of FGF18. Remedium’s scientists discover and develop therapies by appropriately matching treatment modalities with specific disease pathophysiology to replace or augment missing, degenerated, or damaged tissues. Remedium’s pipeline includes gene therapy treatments in the fields of Rheumatology, Endocrinology, Neurology, and Immunology. Additional information is available at https://www.remedium-bio.com/.

About Biovian

Biovian is a Contract Development and Manufacturing Organization, CDMO that provides premium services to biotech companies developing innovative gene therapies and biopharmaceuticals. The goal of the company is to turn ideas into products by taking client projects from the laboratory bench to the clinic. Biovian offers its clients One-Stop-Shop GMP CDMO services, with modularity available from gene to finished vial. Biovian is especially focusing on viral vector production and microbial production of recombinant proteins and GMP plasmid DNA. Guided by its Nordic ethos Biovian has established a reputation for delivering high-quality work on time and within budget to a global client base. Additional information is available at https://biovian.com/.

Press Contact:

Taru Värri, Marketing Manager at Biovian
taru.varri@biovian.com
+358 50 3650973

Record changed: 2024-01-20